


CLAIMS

What is claimed:





1. A compound represented by Formula (XIIa), (XIIb), (XIIc), or (XIId), or a
5 pharmaceutically acceptable salt thereof:



wherein n at each occurrence is independently 0, 1, 2, or 3; m1 at each occurrence is independently 1, 2, or 3; m2 at each occurrence is independently 0, 1, or 2; m4 at each occurrence is independently 0, 1, or 2; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; R₁₁ at each occurrence is independently selected from the group consisting of hydrogen, halogen, hydroxy, protected hydroxy, -CN, amino, protected amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, optionally substituted -NH-C₁-C₆ alkyl, optionally substituted -N(C₁-C₆ alkyl)₂, -CO₂H, optionally substituted -C(O)₂-C₁-C₆

alkyl, optionally substituted -C(O)NH-C₁-C₆ alkyl, and optionally substituted -C(O)-C₁-C₆ alkyl; R₂₁ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, and optionally substituted C₃-C₈ cycloalkyl; R₂₂ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, optionally substituted aryl, and optionally substituted heteroaryl; R₃₀ is hydrogen, optionally substituted -C₁-C₆ alkyl, a hydroxy protecting group or a hydroxy prodrug group; R₃₁ is independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, and optionally substituted 3- to 8-membered heterocyclic.


2. A compound represented by Formula (XIIIa), (XIIIb), (XIIIc), or (XIIId), or a pharmaceutically acceptable salt thereof:



wherein n at each occurrence is independently 0, 1, 2, or 3; m₁ at each occurrence is independently 1, 2, or 3; m₂ at each occurrence is independently 0, 1, or 2; m₄ at each occurrence is independently 0, 1, or 2; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -

N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; R₁₁ at each occurrence is independently selected from the group consisting of hydrogen, halogen, hydroxy, protected hydroxy, -CN, amino, protected amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, optionally substituted -NH-C₁-C₆ alkyl, optionally substituted -N(C₁-C₆ alkyl)₂, -CO₂H, optionally substituted -C(O)₂-C₁-C₆ alkyl, optionally substituted -C(O)NH-C₁-C₆ alkyl, and optionally substituted -C(O)-C₁-C₆ alkyl; R₂₁ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, and optionally substituted C₃-C₈ cycloalkyl; R₂₂ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, optionally substituted aryl, and optionally substituted heteroaryl; R₃₀ is hydrogen, optionally substituted -C₁-C₆ alkyl, a hydroxy protecting group or a hydroxy prodrug group; R₃₂ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted -C(O)-C₁-C₆ alkyl, optionally substituted -C(O)-C₂-C₈ alkenyl, optionally substituted -C(O)-C₂-C₈ alkynyl, optionally substituted -C(O)-C₃-C₈ cycloalkyl, optionally substituted -C(O)-aryl, optionally substituted -C(O)-(3- to 8-membered heterocyclic), optionally substituted -C(O)-C₁-C₆ alkyl, optionally substituted -CO₂-C₁-C₆ alkyl, optionally substituted S(O)₂-C₁-C₆ alkyl, optionally substituted S(O)₂-C₂-C₆ alkenyl.





3. A compound, represented by Formula (XIVa), (XIVb), (XIVc), or (XIVd), or a pharmaceutically acceptable salt thereof:



- wherein n at each occurrence is independently 0, 1, 2, or 3; $m1$ at each occurrence is independently 1, 2, or 3; $m2$ at each occurrence is independently 0, 1, or 2; $m4$ at each occurrence is independently 0, 1, or 2; E at each occurrence is independently selected from
- 5 $-\text{C}(\text{R}_{10})_2-$, $-\text{N}(\text{R}_{10})-$, O , S , $\text{S}(\text{O})$, and $\text{S}(\text{O})_2$; R_{10} at each occurrence is independently selected from the group consisting of hydrogen, halo, $-\text{CN}$, $-\text{NO}_2$, optionally substituted $-\text{C}_1$ - C_6 alkyl, optionally substituted $-\text{C}_2$ - C_8 alkenyl, optionally substituted $-\text{C}_2$ - C_8 alkynyl, optionally substituted $-\text{C}_3$ - C_8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and $-\text{L}_1-\text{R}_1$;
 - 10 wherein L_1 is $-\text{O}-$, $-\text{S}-$, $-\text{NR}_1-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})-$, $-\text{C}(\text{O})\text{N}(\text{R}_1)-$, $-\text{N}(\text{R}_1)\text{C}(\text{O})-$, $-\text{OC}(\text{O})\text{N}(\text{R}_1)-$, $-\text{N}(\text{R}_1)\text{C}(\text{O})\text{O}-$, $-\text{N}(\text{R}_1)\text{C}(\text{O})\text{N}(\text{R}_1)-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{S}(\text{O})_2\text{N}(\text{R}_1)-$, $-\text{N}(\text{R}_1)\text{S}(\text{O})_2-$; R_1 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted $-\text{C}_1$ - C_6 alkyl, optionally substituted $-\text{C}_2$ - C_8 alkenyl, optionally substituted $-\text{C}_2$ - C_8 alkynyl, optionally substituted $-\text{C}_3$ - C_8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; R_{11} at each occurrence is independently selected from the group consisting of hydrogen, halogen, hydroxy, protected hydroxy, $-\text{CN}$, amino, protected amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted $-\text{C}_1$ - C_6 alkyl, optionally substituted $-\text{C}_2$ - C_8 alkenyl, optionally substituted $-\text{C}_2$ - C_8 alkynyl, optionally substituted $-\text{C}_3$ - C_8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted $-\text{C}_1$ - C_6 alkoxy, optionally substituted $-\text{NH}-\text{C}_1$ - C_6 alkyl, optionally substituted $-\text{N}(\text{C}_1$ - C_6 alkyl) $_2$, $-\text{CO}_2\text{H}$, optionally substituted $-\text{C}(\text{O})_2$ - C_1 - C_6 alkyl, optionally substituted $-\text{C}(\text{O})\text{NH}-\text{C}_1$ - C_6 alkyl, and optionally substituted $-\text{C}(\text{O})-\text{C}_1$ - C_6 alkyl; R_{21} at each occurrence is independently selected from the group consisting of
 - 20 halogen, CN , optionally substituted $-\text{C}_1$ - C_6 alkyl, optionally substituted $-\text{C}_1$ - C_6 alkoxy, and optionally substituted C_3 - C_8 cycloalkyl; R_{22} at each occurrence is independently selected
 - 25

from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, optionally substituted aryl, and optionally substituted heteroaryl; R₃₀ is hydrogen, optionally substituted -C₁-C₆ alkyl, a hydroxy protecting group or a hydroxy prodrug group; R₃₃ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, optionally substituted -NH-C₁-C₆ alkyl, optionally substituted -N(C₁-C₆ alkyl)₂, optionally substituted -NH-C₁-C₆ alkenyl, optionally substituted -NH-(3- to 8-membered heterocyclic).

4. A compound represented by Formula (XVa), (XVb), (XVc), or (XVd), or a pharmaceutically acceptable salt thereof:




wherein n at each occurrence is independently 0, 1, 2, or 3; m₁ at each occurrence is independently 1, 2, or 3; m₂ at each occurrence is independently 0, 1, or 2; m₄ at each occurrence is independently 0, 1, or 2; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl,

optionally substituted $-C_2-C_8$ alkynyl, optionally substituted $-C_3-C_8$ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; R_{11} at each occurrence is independently selected from the group consisting of hydrogen, halogen, hydroxy, protected hydroxy, $-CN$, amino, protected amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted $-C_1-C_6$ alkyl, optionally substituted $-C_2-C_8$ alkenyl, optionally substituted $-C_2-C_8$ alkynyl, optionally substituted $-C_3-C_8$ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted $-C_1-C_6$ alkoxy, optionally substituted $-NH-C_1-C_6$ alkyl, optionally substituted $-N(C_1-C_6 \text{ alkyl})_2$, $-CO_2H$, optionally substituted $-C(O)_2-C_1-C_6$ alkyl, optionally substituted $-C(O)NH-C_1-C_6$ alkyl, and optionally substituted $-C(O)-C_1-C_6$ alkyl; R_{21} at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted $-C_1-C_6$ alkyl, optionally substituted $-C_1-C_6$ alkoxy, and optionally substituted C_3-C_8 cycloalkyl; R_{22} at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted $-C_1-C_6$ alkyl, optionally substituted $-C_1-C_6$ alkoxy, optionally substituted aryl, and optionally substituted heteroaryl; R_{30} is hydrogen, optionally substituted $-C_1-C_6$ alkyl, a hydroxy protecting group or a hydroxy prodrug group; R_{31} is independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted $-C_1-C_6$ alkyl, optionally substituted $-C_2-C_8$ alkenyl, optionally substituted $-C_2-C_8$ alkynyl, optionally substituted $-C_3-C_8$ cycloalkyl, and optionally substituted 3- to 8-membered heterocyclic; R_{34} at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted $-C_2-C_8$ alkenyl, optionally substituted $-C_2-C_8$ alkynyl, optionally substituted $-C_3-C_8$ cycloalkyl, and optionally substituted 3- to 8-membered heterocyclic.

25

5. A compound represented by Formula (XVI), or a pharmaceutically acceptable salt thereof:




wherein R_{21} , R_{21}' and R_{21}'' are independently selected from hydrogen, fluorine, methyl, difluoromethyl, and trifluoromethyl; and R_{35} is $-[CH(R_{36})]_p-C(R_{37})(R_{38})OH$ or $-CH_2-O-$

30

$\text{CH}_2-[\text{CH}(\text{R}_{36})]_p-\text{C}(\text{R}_{37})(\text{R}_{38})\text{OH}$, wherein p is 0 or 1; R_{36} is hydrogen, methyl or hydroxyl and R_{37} and R_{38} are independently hydrogen or methyl.










6. A compound represented by Formula (XVII), or a pharmaceutically acceptable salt thereof:




















- wherein R_{21} , R_{21}' and R_{21}'' are independently selected from hydrogen, fluorine, methyl, difluoromethyl, and trifluoromethyl; R_{39} is hydrogen or hydroxyl; and R_{40} is $-\text{[C}(\text{R}_{41})(\text{R}_{42})\text{]}_q-\text{R}_{43}$, wherein q is 0, 1 or 2; R_{41} and R_{42} are each independently hydrogen, methyl, or hydroxyl; or alternatively, R_{41} and R_{42} can be taken together to form an oxo; and R_{43} is hydrogen, hydroxyl, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_3\text{-C}_6$ cycloalkyl, optionally substituted 3- to 12-membered heterocyclic, optionally substituted aryl or optionally substituted heteroaryl.










7. A compound selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:










Compound	Structure
1	
2	
3	










4	 <i>racemic</i>
5	 <i>racemic</i>
6	
7	
8	
9	
10	
11	
12	










13	
14	
15	
16	
17	
18	
19	
20	










21	
22	
23	
24	
25	 cis and racemic
26	
27	 HCl
28	
29	










30	
31	
32	
33	
34	
35	
36	
37	
38	










39	
40	
41	
42	 * Relative Stereochemistry
43	
44	
45	
46	
47	










48	
49	
50	
51	
52	
53	
54	
55	
56	










57	
58	
59	 * Relative Stereochemistry
60	 racemic
61	
62	
63	
64	
65	











66	
67	
68	
69	
70	
71	
72	
73	
74	










75	
76	
77	
78	
79	
80	
81	
82	
83	










84	
85	
86	
87	
88	
89	
90	
91	
92	










93	
94	
95	
96	
97	
98	
99	
100	
101	










102	
103	
104	
105	
106	
107	
108	
109	
110	










111	
112	
113	
114	
115	
116	
117	
118	
119	
120	










121	
122	
123	
124	
125	
126	
127	
128	
129	










130	
131	
132	
133	
134	
135	
136	
137	
138	










139	
140	
141	
142	
143	
144	
145	
146	
147	










148	
149	
150	
151	
152	
153	
154	
155	
156	










157	
158	
159	
160	
161	
162	
163	
164	
165	

166	
167	
168	
169	
170	
171	
172	 racemic
173	 racemic
174	










175	
176	
177	
178	
179	
180	
181	
182	
183	










184	
185	
186	
187	
188	
189	
190	
191	
192	








193	
194	
195	
196	
197	
198	
199	
200	
201	









202	
203	
204	
205	
206	
207	
208	
209	
210	 Racemic










211	4:1 mixture
212	
213	
214	
215	
216	
217	
218	
219	









220	
221	
222	
223	
224	
225	
226	
227	
228	









229	
230	
231	
232	
233	
234	
235	
236	
237	










238	
239	
240	
241	
242	
243	
244	











245	
246	
247	
248	
249	
250a	
250b	
251	










252	
252a	
252b	
253a	
253b	
254	
255	
256	
256a	











256b	
257a	
257b	
258	
260	
261	
262	
263	










264	
265	
266	
267	
268	
269	
270	
271	











272	
273	
274	
275	
276	
277	
278	
279	
280	










281	
282	
283	
284	
284a	
284b	
285	
285a	
285b	
286	










287	
288	
289	
290	
291	
291a	
291b	
292	
293	

294	
294a	
294b	
295	
295a	
295b	
296	
296a	
296b	
297	










297a	
297b	
298	
299	
300	
301	
302	
302a	
302b	










303	
304	
305	
306	
307	
308	
309	
310	
311	
312	










313	
314	
315	
316	
317	
318	
319	
320	
321	










322	
323	
324	
325	
326	
327	
328	
329	
330	

331	
332	
333	
334	
335	
336	
337	
338	
339	

340	
341	
342	
343	 3.5:1, two isomers
344	
345	
346	
347	
348	

349	
350	
351	
352	
353	
354	
355	
356	
357	

358	
359	
360	
361	
362	
363	
364	
365	
366	

368	
369	
370	
371	
372	
373	
374	
375	
376	

8. A pharmaceutical composition, comprising a compound according to any one of claims 1-7 and a pharmaceutically acceptable carrier or excipient.
9. A method of treating or preventing an HBV infection in a subject in need thereof,
5 comprising administering to the subject a therapeutically effective amount of a compound or a combination of compounds according to any one of claims 1-7.
10. The method of claim 9, further comprising administering to the subject at least one additional therapeutic agent selected from the group consisting of HBV polymerase
10 inhibitors, interferon, viral entry inhibitors, viral maturation inhibitors, capsid assembly or core protein inhibitors or modulators, reverse transcriptase inhibitors, TLR-agonists, inducers of cellular viral RNA sensor, therapeutic vaccines, RNA interference (RNAi) or small interfering RNA (siRNA) and combinations thereof.
- 15 11. The method of claim 10, wherein the compound and the at least one additional therapeutic agent are co-formulated.
12. The method of claim 10, wherein the at least one additional therapeutic agent is administered at a lower dose and/or frequency than that which is therapeutically effective
20 when said agent is administered alone.